Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hereditary angioedema
Biotech
KalVista sells Japanese rights for HAE drug to Kaken
As KalVista waits for an FDA decision on sebetralstat, the company has sold the Japanese rights to Kaken for $11 million upfront.
James Waldron
Apr 8, 2025 8:35am
Poseida gene therapy reduces kallikrein protein levels in mice
Oct 24, 2024 1:20pm
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks
Oct 24, 2024 8:55am
Pharming uproots angioedema gene therapy collab with Orchard
May 8, 2024 6:15am
With new data in hand, Astria makes ph. 3 wish on shooting star
Mar 25, 2024 10:46am
KalVista's persistence with sebetralstat pays off in ph. 3 win
Feb 13, 2024 6:30am
